Corrigendum: Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab. [Ann Oncol 27, (2016), (732-738)] doi:10.1093/annonc/mdw016.;Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab

Annals of Oncology

Volumn 27, Issue 4, 2016, Pages 732-738

  Ferrucci, P F ^a   Ascierto, P A ^b   Pigozzo, J ^c   Del Vecchio, M ^d   Maio, M ^e   Antonini Cappellini, G C ^f   Guidoboni, M ^g   Queirolo, P ^h   Savoia, P ⁱ   Mandala M ^j   Simeone, E ^b   Valpione, S ^c   Altomonte, M ^e   Spagnolo, F ^h   Cocorocchio, E ^a   Gandini, S ^a   Giannarelli, D ^k   Martinoli, C ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY HOSPITAL OF SIENA   (Italy)

^f LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^g DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^k REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

Biomarker; dNLR; Ipilimumab; Melanoma; Neutrophil; Prognosis

Indexed keywords

IPILIMUMAB; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY; TUMOR MARKER;

AGE; ARTICLE; BLOOD CELL COUNT; BRAIN METASTASIS; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE COURSE; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; FEMALE; FOLLOW UP; GENDER; HUMAN; HUMAN CELL; INDEPENDENT VARIABLE; ITALY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MORTALITY; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; NEUTROPHILIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; ADOLESCENT; ADULT; AGED; BLOOD; DISEASE FREE SURVIVAL; LYMPHOCYTE; LYMPHOCYTE COUNT; MELANOMA; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ITALY; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MELANOMA; MIDDLE AGED; NEUTROPHILS; PROGNOSIS;

EID: 84964620722     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx059     Document Type: Erratum

References (24)

1. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
2. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
3. Kelderman S, Heemskerk B, van Tinteren H et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 2014; 63: 449-458.
4. Berrocal A, Arance A, Lopez Martin JA et al. Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program. Melanoma Res 2014; 24: 577-583.
5. Ku GY, Yuan J, Page DB et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116: 1767-1775.
6. Wilgenhof S, Du Four S, Vandenbroucke F et al. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother 2013; 36: 215-222.
7. Simeone E, Gentilcore G, Giannarelli D et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 2014; 63: 675-683.
8. Delyon J, Mateus C, Lefeuvre D et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 2013; 24: 1697-1703.
9. Valpione S, Martinoli C, Fava P et al. Personalised medicine: development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. Eur J Cancer 2015; 51: 2086-2094.
10. Di Giacomo AM, Ascierto PA, Queirolo P et al. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol 2015; 26: 798-803.
11. Ferrucci PF, Gandini S, Battaglia A et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer 2015; 112: 1904-1910.
12. Zaragoza J, Caille A, Beneton N et al. Neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol 2016; 174: 146-151.
13. Proctor MJ, McMillan DC, Morrison DS et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 2012; 107: 695-699.
14. Ascierto PA, Simeone E, Sileni VC et al. Clinical experience with ipilimumab 3 mg/ kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014; 12: 116.
15. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420.
16. Rice L, Jung M. Hematology: Basic Principle and Practice, 6th edition. Philadelphia, PA: Elsevier Health Sciences 2013.
17. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
18. Maio M, Grob JJ, Aamdal S et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015; 33: 1191-1196.
19. Schadendorf D, Hodi FS, Robert C et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33: 1889-1894.
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
21. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014; 15: e493-e503.
22. Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol 2013; 23: 200-207.
23. Templeton AJ, McNamara MG, Seruga B et al. Prognostic role of neutrophil-tolymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106: dju124.
24. Schmidt H, Suciu S, Punt CJ et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 2007; 25: 1562-1569.